cor2ed
engage checkpoint medical linkedin twitter
bg

BluePrint resource: PCSK9 inhibitor therapies in ACS

BluePrint resource: PCSK9 inhibitor therapies in ACS

Prof. Dr. Anna Franzone, Prof. Dr. Jeanine Roeters van Lennep, Prof. Dr. Uwe Zeymer, Dr. Flavien Vincent, Prof. Dr. Zuzana Motovska

Portrait of Anna Franzone
Prof. Dr. Anna Franzone

Cardiologist

Federico II University of Naples

Italy

Portrait of Jeanine Roeters van Lennep
Prof. Dr. Jeanine Roeters van Lennep

Internist, Vascular Medicine

Erasmus Medical Center

Netherlands

Portrait of Uwe Zeymer
Prof. Dr. Uwe Zeymer

Cardiologist

Heart Center Ludwigshafen

Germany

Portrait of Flavien Vincent
Dr. Flavien Vincent

Cardiologist

Lille University Hospital

France

Portrait of Zuzana Motovska
Prof. Dr. Zuzana Motovska

Cardiologist

Charles University

Czech Republic

preview next

time BluePrint Resource | open 10 min | Sep 2021

temporal

I agree that this educational programme:

Early (in-hospital) initiation of PCSK9 inhibitor therapy in patients with acute coronary syndrome may provide additional clinical benefit when used on top of statin treatment. This BluePrint describes current recommendations regarding low-density lipoprotein cholesterol targets in patients with ACS, the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rationale for its inhibition in ACS, and the expected clinical impact of PCSK9 inhibitors in the acute phase of ACS.

Development of this BluePrint was supported by an Independent Educational Grant from Amgen.

CORONARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Amgen.

Other programmes of interest

preview next